1Suzatani T, Machida H, Sukuma T, et al, Effects of various nucleosides on antiviral acitivity and metabolism of 1-β-D-arabino-furanosyl-E-5 (2-bromovinyl) uracil against herps 1 and 2.Antimicrob Agents Chemother, 1988. 32:1547
2Lin JC, Machida H. Comparison of two bromovinyl nucleoside analogs, 1-β-D-arabino-furanosyl-E-5 ( 2-bromovinyl )-2-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimicrob Agents Chemother, 1988, 32:1068
3Machida H, Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol Immunol, 1990, 34:407
4Nakamura H, Omori S, Kitada K, et al. Prevention of drug interactions and its countermeasure. J Toxicol Sci, 1994,19:89
5Okuda H, Nishiyama T, Ogura K, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug-Metab-Dispos, 1997,25 (5): 270
6Daher GC, Harris BE. Diasio RB. Metabolism of pyrimidine analogues and their nucleosides, In: Metabolism and reactions of anticancer drugs, Vol. 1, In the International Encyclopedia of Pharmacology and Therapeutics, Oxford, pergamon Press, 1994. Chap 2
7Yan J, Tyring SK, McCrary MM, et al. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin Pharmacol Ther. 1997,61:563
8Johnson MJ, Yan J, Albin N, et al. Rapid Screening for Dihydropyrimidine Dehydrogenase (DPD) Deficiency, A Condition Associated with 5-Fluorouracil Toxicity. J chromatography Biomed Applications, 1997, 696:183
9Spector T, Porter DJT, Nelson DJ, et al. 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouacil. Drugs of the Future. 1994,19:566
10Harris BE, Song R. He Y, et al. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase: Possible relevance to flourophrimindine chemotherapy. Biochem Pharmacol, 1988,37:4759
